IN2012DN02073A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02073A
IN2012DN02073A IN2073DEN2012A IN2012DN02073A IN 2012DN02073 A IN2012DN02073 A IN 2012DN02073A IN 2073DEN2012 A IN2073DEN2012 A IN 2073DEN2012A IN 2012DN02073 A IN2012DN02073 A IN 2012DN02073A
Authority
IN
India
Prior art keywords
hcg
including recombinant
preparations including
preparations
recombinant hcg
Prior art date
Application number
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of IN2012DN02073A publication Critical patent/IN2012DN02073A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2073DEN2012 2009-10-05 2010-10-04 IN2012DN02073A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
PCT/GB2010/001854 WO2011042688A1 (fr) 2009-10-05 2010-10-04 Préparation pharmaceutique comprenant une hcg recombinante

Publications (1)

Publication Number Publication Date
IN2012DN02073A true IN2012DN02073A (fr) 2015-08-21

Family

ID=41471027

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2073DEN2012 IN2012DN02073A (fr) 2009-10-05 2010-10-04

Country Status (25)

Country Link
US (5) US8975226B2 (fr)
EP (2) EP3611185A1 (fr)
JP (6) JP6176924B2 (fr)
KR (7) KR20210014767A (fr)
CN (1) CN107050434B (fr)
AR (2) AR079876A1 (fr)
AU (1) AU2010304922B2 (fr)
BR (1) BR112012007990A2 (fr)
CA (1) CA2776790A1 (fr)
DK (1) DK2486051T3 (fr)
ES (1) ES2798258T3 (fr)
HR (1) HRP20200941T1 (fr)
HU (1) HUE050793T2 (fr)
IL (3) IL218548A (fr)
IN (1) IN2012DN02073A (fr)
JO (1) JOP20200039A1 (fr)
LT (1) LT2486051T (fr)
MX (1) MX2012003951A (fr)
PL (1) PL2486051T3 (fr)
PT (1) PT2486051T (fr)
RS (1) RS60413B1 (fr)
RU (2) RU2724528C2 (fr)
SI (1) SI2486051T1 (fr)
TW (2) TWI532495B (fr)
WO (1) WO2011042688A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (fr) 2011-03-31 2012-10-04 Ferring B.V. Préparation pharmaceutique
EP2717904A1 (fr) * 2011-06-06 2014-04-16 Ferring BV Préparation pharmaceutique
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (fr) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, procédés et trousses pour la préparation de protéines recombinantes sialylées
SG11201504564TA (en) 2012-12-10 2015-08-28 Seikagaku Kogyo Co Ltd Novel recombinant factor c and method for producing the same, and method for measuring endotoxin
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
DK3286209T3 (da) * 2015-04-24 2020-12-21 Ferring Bv Fremgangsmåde til fremstilling af gonadotrophin
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation
EP3787667A1 (fr) * 2018-04-30 2021-03-10 Ferring B.V. Composition destinée à la stimulation ovarienne contrôlée
MX2022009611A (es) * 2020-02-05 2022-11-07 Novartis Ag Celula cho que expresa heterodimeros il-15.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
EP0814841B1 (fr) * 1995-03-21 2001-12-05 Applied Research Systems ARS Holding N.V. Compositions liquides de gonadotrophine chorionique de l'homme
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
JP3950484B2 (ja) 1997-06-25 2007-08-01 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ ジスルフィド架橋結合した糖タンパク質ホルモン類似体類およびそれらの調製および使用
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
CA2372714A1 (fr) 1999-05-07 2000-11-16 Stephen Franks Gonadotrophines
CA2399020A1 (fr) * 2000-02-22 2001-08-30 Applied Research Systems Ars Holding N.V. Procede de purification de hcg et hcg recombinee purifiee par cette methode
RS21004A (en) 2001-09-12 2006-12-15 Aplied Research Systems Ars Holding N.V. Use of hcg in controlled ovarian hyperstimulation
AU2002340562B2 (en) * 2001-10-22 2008-10-23 Merck Serono Sa Compositions of FSH with high sialylation degree and their use for the preparation of medicaments
ES2381104T3 (es) * 2001-10-29 2012-05-23 Crucell Holland B.V. Métodos y medios para producir proteínas con modificaciones postraduccionales predeterminadas
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
MXPA05010773A (es) * 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US8017388B2 (en) * 2003-08-18 2011-09-13 Glycotope Gmbh Tumour cell lines and uses thereof
US8431355B2 (en) * 2004-02-04 2013-04-30 Universite De Provence Aix-Marseille 1 Process for screening glycoform-specific antibodies
EP1725673A1 (fr) * 2004-02-13 2006-11-29 Glycotope Gmbh Conditions de traitement de glycoproteines extremement actives et methode efficace de production associee
KR20070110902A (ko) * 2005-03-11 2007-11-20 프레제니우스 카비 도이치란트 게엠베하 비활성 출발 물질로부터 생물활성 당단백질의 생산
US20070033927A1 (en) 2005-08-15 2007-02-15 Homby Michael J Automotive diesel exhaust HC dosing valve
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 dna칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2054521A4 (fr) * 2006-10-03 2012-12-19 Novo Nordisk As Méthodes de purification de conjugués de polypeptides
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (fr) * 2011-03-31 2012-10-04 Ferring B.V. Préparation pharmaceutique
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
JP6176924B2 (ja) 2017-08-09
IL218548A (en) 2017-03-30
KR20190028823A (ko) 2019-03-19
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
RU2588650C2 (ru) 2016-07-10
JP7292153B2 (ja) 2023-06-16
JP2023075144A (ja) 2023-05-30
RU2016118236A3 (fr) 2019-09-18
WO2011042688A1 (fr) 2011-04-14
JP2021176867A (ja) 2021-11-11
US9676835B2 (en) 2017-06-13
KR101987982B1 (ko) 2019-06-11
HUE050793T2 (hu) 2021-01-28
BR112012007990A2 (pt) 2017-07-25
US11292824B2 (en) 2022-04-05
US8975226B2 (en) 2015-03-10
KR20170133531A (ko) 2017-12-05
MX2012003951A (es) 2012-05-29
JP6310440B2 (ja) 2018-04-11
LT2486051T (lt) 2020-07-10
AR125991A2 (es) 2023-08-30
IL250733B (en) 2019-07-31
RU2016118236A (ru) 2018-10-29
US20200247863A1 (en) 2020-08-06
JP2020000246A (ja) 2020-01-09
PL2486051T3 (pl) 2020-09-07
JOP20200039A1 (ar) 2022-10-30
PT2486051T (pt) 2020-06-17
RU2012112907A (ru) 2013-11-10
TW201113030A (en) 2011-04-16
US20140249082A1 (en) 2014-09-04
EP2486051B1 (fr) 2020-03-25
KR20210014767A (ko) 2021-02-09
JP7196244B2 (ja) 2022-12-26
TWI532495B (zh) 2016-05-11
US20220340634A1 (en) 2022-10-27
IL250733A0 (en) 2017-04-30
EP3611185A1 (fr) 2020-02-19
KR101804479B1 (ko) 2017-12-05
KR102489143B1 (ko) 2023-01-13
KR20190067256A (ko) 2019-06-14
JP6580104B2 (ja) 2019-09-25
TW201632198A (zh) 2016-09-16
EP2486051A1 (fr) 2012-08-15
CN107050434A (zh) 2017-08-18
KR20210141771A (ko) 2021-11-23
AU2010304922A1 (en) 2012-03-29
KR20230012104A (ko) 2023-01-25
IL267556A (en) 2019-08-29
RS60413B1 (sr) 2020-07-31
SI2486051T1 (sl) 2020-08-31
CN107050434B (zh) 2021-07-27
JP2016074680A (ja) 2016-05-12
ES2798258T3 (es) 2020-12-10
CN102549011A (zh) 2012-07-04
DK2486051T3 (da) 2020-06-22
JP2013506708A (ja) 2013-02-28
IL218548A0 (en) 2012-05-31
RU2724528C2 (ru) 2020-06-23
KR102213154B1 (ko) 2021-02-05
AU2010304922B2 (en) 2014-11-06
US10526390B2 (en) 2020-01-07
HRP20200941T1 (hr) 2020-09-18
CA2776790A1 (fr) 2011-04-14
JP2018076296A (ja) 2018-05-17
AR079876A1 (es) 2012-02-29
US20180030107A1 (en) 2018-02-01
US20130023476A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
EP4302783A3 (fr) Polypeptides de relaxine modifiés et leurs utilisations
MX355457B (es) Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion.
IN2012DN06714A (fr)
IN2011KN03851A (fr)
UA103774C2 (uk) Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
AU334234S (en) Clamp for fence panels
IN2012DN04748A (fr)
IN2012DN04414A (fr)
JO3755B1 (ar) تركيبات تستوستيرون
MX2012006980A (es) Polipeptidos de somatotropina porcina modificados y sus usos.
MX349301B (es) Polipéptidos de somatotropina bovina modificados y sus usos.
IN2011KN03928A (fr)
MY168248A (en) Next-instruction-type field
JO3497B1 (ar) مستحضر صيدلي يشتمل على hcg مأشوب
GB2491544A (en) Perpetum mobile
IN2012DN04805A (fr)
UA42262U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-METHYLTHIOXANTINE EXHIBITING DIURETIC ACTION
AU313101S (en) Glass balustrading clamp - Frameless
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
CL2009001949S1 (es) Cajero automatico.
AU333244S (en) Control panel
AU325379S (en) Scarves
UA34276U (ru) 7-β-ГИДРОКСИЭТИЛ-3-МЕТИЛ-8-N-ПИРРОЛИДИНОКСАНТИН, КОТОРЫЙ ПРОЯВЛЯЕТ ДИУРЕТИЧЕСКОЕ ДЕЙСТВИЕ
CL2009001548S1 (es) Sillon.